SCHEMBL3754896

SCHEMBL3754896

CN(C)CCNc1ccc(I)cn1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.56
TDO2 P48775 1/20 0.48
HRH3 Q9Y5N1 1/20 0.47
DNM2 P50570 4/20 0.42
HRH4 Q9H3N8 1/20 0.41
GAA P10253 1/20 0.38
ALPG P10696 1/20 0.38
EGFR P00533 2/20 0.38
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
EDNRA P25101 1/20 0.37
HCAR3 P49019 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MKNK1 Q9BUB5 1/20 0.37
TLR7 Q9NYK1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25997110 0.90 CYP2C19 (0.45) CYP2C19TDO2HRH3DNM2EGFR
SCHEMBL12060 0.81 CYP2C19 (0.57) CYP2C19TDO2HRH3DNM2HRH4
SCHEMBL18307133 0.80 HCAR3 (0.56) EDNRAHCAR3HPGDSMN1; SMN2
SCHEMBL2679914 0.79 CYP2C19 (0.56) CYP2C19TDO2HRH3DNM2HRH4
SCHEMBL31260395 0.79 CYP2C19 (0.56) CYP2C19TDO2HRH3DNM2HRH4
SCHEMBL15828790 0.79 CYP2C19 (0.56) CYP2C19TDO2HRH3DNM2HRH4
SCHEMBL11446598 0.79 CYP2C19 (0.56) CYP2C19TDO2HRH3DNM2HPGD
SCHEMBL22792337 0.78 CYP2C19 (0.54) CYP2C19TDO2HRH3DNM2HRH4
SCHEMBL12449618 0.77 CYP2C19 (0.53) CYP2C19TDO2HRH3DNM2HRH4
SCHEMBL6361877 0.77 CYP2C19 (0.53) CYP2C19TDO2HRH3DNM2HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4716685-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-04-01 EP disclosed
WO-2024240726-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-11-28 WO disclosed
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA CYP2C19 1473/4885TDO2 1728/4885HRH3 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.